amuser
#41
My Bemdac is made by a different contract manufacturer.
I’m not on it right now, but I’m pretty sure it works.
First, I went with ezetimibe only, and that cut ldl in half. Then I switched to the above, and ldl appeared to drop a bit further, but not as dramatic a change as ezetimibe. It was as least as good as ezet alone, maybe 5-10% better. ATM, I’m only on ezet only, for reasons.
3 Likes
Interesting… my Zydus Bemdac is made by another manufacturer… and while I’ve had good results with this medication, it doesn’t make me happy that they don’t make the medicine themselves.
Seems like Zydus (and probably others) use a bunch of contract manufacturers for some of their medications:
https://www.exemedpharma.com
2 Likes
amuser
#43
The stateside, patent-covered tablets are made in India.
I would take the specifics above with a grain of salt, but the actual label does say ‘Made in India’.
3 Likes
Beth
#44
Excellent find @amuser because my solution to all of this was to go back to taking nexletol
I don’t doubt Brillo EZ works as many of you have taken it with success, but it’s the safety issue about something being made in a potentially subpar facility I was trying to avoid. (I assume I am preaching to the choir)
Nexletol also says ‘manufactured for’
3 Likes
Yeah, it’s the potential contamination with lead and heavy metal contaminants
Given uncertainties, it may be a good idea to just get from a trustable source (eg Ezemibe (Ezetimibe) - United Pharmacies ) and self-test. There isn’t a fully trustworthy source of nexlizet but it’s not like I have emergency levels of LDL
1 Like
I asked DeepSeek:
Akums Drugs & Pharmaceuticals Ltd. is a prominent Indian contract manufacturing organization (CMO) in the pharmaceutical sector. Here’s a detailed overview:
Background
-
Established: 2004 in Haridwar, Uttarakhand, India.
-
Headquarters: Haridwar, a strategic location in northern India with industrial and regulatory advantages.
Core Operations
-
Specialization: Contract manufacturing of generic drugs, producing formulations for third-party companies (domestic and international).
-
Product Range: Diverse portfolio including tablets, capsules, injectables, syrups, ointments, and more across therapeutic areas like cardiology, neurology, antibiotics, and diabetology.
-
Facilities: State-of-the-art manufacturing units with advanced technology, adhering to global quality standards.
Regulatory Compliance
-
Certifications: WHO-GMP, US FDA, UK MHRA, and other international approvals, enabling exports to regulated markets (e.g., US, Europe, Africa, Asia).
-
Quality Focus: Emphasis on compliance and rigorous quality control to meet client and regulatory requirements.
Scale & Impact
-
Capacity: Over 5,000 formulations and 10 manufacturing units, making it one of India’s largest CMOs.
-
Employment: Employs thousands, contributing significantly to local and national economies.
-
Clients: Partners with leading Indian and multinational pharma companies, enhancing global access to affordable medicines.
Market Position
-
Competitive Edge: Known for cost-effectiveness, reliability, and scalability in production.
-
Challenges: Navigates competitive pricing, regulatory scrutiny, and maintaining quality at scale.
Recent Developments
-
Expansion: Continues to invest in facility upgrades and technology to meet growing demand.
-
Innovation: Explores complex generics and niche therapeutic segments.
Impact
-
Affordability: Plays a key role in reducing drug costs globally, particularly in emerging markets.
Controversies
- No major public scandals reported, though routine regulatory inspections are part of operations.
Summary
Akums is a critical player in India’s pharmaceutical landscape, leveraging its manufacturing prowess and compliance focus to serve global markets. Its growth reflects India’s strength in generic drug production and contract manufacturing.
3 Likes
amuser
#47
Must been trained on a marketing brochure.
4 Likes
Based on what I found through Google, Akums has had drug recalls averaging about 1 every 2 years. That means that it is not without risk, but based on the sheer number of generics they manufacture, the recall rate seems quite low. In addition, many of the recalls were not life-threatening. They tended to be relatively harmless - ‘less of the drug than the advertised’ type. When you’re getting your generics from India at a 90% discount, you do take your chances.
The problem is, if we had to pay 10X more for each drug, we probably wouldn’t be able to take them. So, is an untreated problem worse than the chance that a drug may have a recall? I’d say so. So, I’ll stick with my generics.
3 Likes
